Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
Graham LS, True LD, Gulati R, Schade GR, Wright J, Grivas P, Yezefski T, Nega K, Alexander K, Hou WM, Yu EY, Montgomery B, Mostaghel EA, Matsumoto AA, Marck B, Sharifi N, Ellis WJ, Reder NP, Lin DW, Nelson PS, Schweizer MT.
Graham LS, et al.
Prostate. 2021 May;81(7):418-426. doi: 10.1002/pros.24118. Epub 2021 Mar 23.
Prostate. 2021.
PMID: 33755225
Free PMC article.